Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
1.
Acta Neurochir Suppl ; 123: 147-51, 2016.
Article de Anglais | MEDLINE | ID: mdl-27637642

RÉSUMÉ

Seizures are common symptoms of supratentorial arteriovenous malformations (AVMs). The potential risk factors for epilepsy in patients with AVMs are still controversial. The reported long-term outcome of seizures after surgical treatment of AVMs is variable and the data available are mainly from small retrospective case series.We identified all consecutive patients between 1990 and 2006 who underwent microsurgical resection of supratentorial AVMs at our institute. Pre-operative risk factors for seizures, intra-operative characteristics, long-term neurological disability, and seizure outcome (Engel's classification) were recorded and analyzed.During the study period, 110 patients underwent surgical resection of supratentorial AVM. Sixty of them (55 %) were symptomatic for seizures preoperatively. In our series, the absence of preoperative neurological deficits (p = 0.005), a large AVM size (p = 0.005), and no history of preoperative AVM hemorrhage (p < 0.001) were identified as risk factors for preoperative seizures. Following surgical resection, 77 % of patients with preoperative seizures had a modified Engel class I outcome. Among patients without a history of preoperative epilepsy, 56 % had new-onset seizures after surgical resection. None of the risk factors associated with preoperative seizures was associated with post-operative seizures. As there are no reliable factors predicting patients who may benefit from surgical treatment, epilepsy control should not be considered as the primary goal of AVMs surgery.


Sujet(s)
Anticonvulsivants/usage thérapeutique , Malformations artérioveineuses intracrâniennes/chirurgie , Microchirurgie , Procédures de neurochirurgie , Complications postopératoires/épidémiologie , Crises épileptiques/traitement médicamenteux , Adolescent , Adulte , Sujet âgé , Enfant , Épilepsie/traitement médicamenteux , Épilepsie/épidémiologie , Épilepsie/étiologie , Épilepsie/physiopathologie , Femelle , Études de suivi , Humains , Malformations artérioveineuses intracrâniennes/complications , Mâle , Adulte d'âge moyen , Études rétrospectives , Facteurs de risque , Crises épileptiques/épidémiologie , Crises épileptiques/étiologie , Crises épileptiques/physiopathologie , Résultat thérapeutique , Jeune adulte
2.
Epilepsy Behav ; 49: 318-24, 2015 Aug.
Article de Anglais | MEDLINE | ID: mdl-25952268

RÉSUMÉ

The treatment of refractory and super refractory status epilepticus is a "terra incognita" from the point of view of evidence-based medicine. As randomized or controlled studies that are sufficiently powered are not feasible in relation to the many therapies and treatment approaches available, we carried out an online multinational audit (registry) in which neurologists or intensivists caring for patients with status epilepticus may prospectively enter patients who required general anesthesia to control the status epilepticus (SE). To date, 488 cases from 44 different countries have been collected. Most of the patients had no history of epilepsy and had a cryptogenic etiology. First-line treatment was delayed and not in line with current guidelines. The most widely used anesthetic of first choice was midazolam (59%), followed by propofol and barbiturates. Ketamine was used in most severe cases. Other therapies were administered in 35% of the cases, mainly steroids and immunotherapy. Seizure control was achieved in 74% of the patients. Twenty-two percent of patients died during treatment, and four percent had treatment actively withdrawn because of an anticipated poor outcome. The neurological outcome was good in 36% and poor in 39.3% of cases, while 25% died during hospitalization. Factors that positively influenced outcome were younger age, history of epilepsy, and low number of different anesthetics tried. This article is part of a Special Issue entitled "Status Epilepticus".


Sujet(s)
Anticonvulsivants/usage thérapeutique , Épilepsie pharmacorésistante/traitement médicamenteux , État de mal épileptique/traitement médicamenteux , Adolescent , Adulte , Facteurs âges , Sujet âgé , Sujet âgé de 80 ans ou plus , Anesthésie générale , Anesthésiques dissociatifs/usage thérapeutique , Anesthésiques intraveineux/usage thérapeutique , Barbituriques/usage thérapeutique , Enfant , Enfant d'âge préscolaire , Épilepsie pharmacorésistante/complications , Épilepsie pharmacorésistante/mortalité , Femelle , Recommandations comme sujet , Enquêtes sur les soins de santé , Humains , Nourrisson , Nouveau-né , Kétamine/usage thérapeutique , Mâle , Audit médical , Midazolam/usage thérapeutique , Adulte d'âge moyen , Maladies du système nerveux/étiologie , Propofol/usage thérapeutique , Études prospectives , Enregistrements , État de mal épileptique/complications , État de mal épileptique/mortalité , Résultat thérapeutique , Jeune adulte
3.
Clin Neuropsychol ; 15(3): 309-13, 2001 Aug.
Article de Anglais | MEDLINE | ID: mdl-11778768

RÉSUMÉ

The Tower of London (TOL) task is frequently used to assess executive functioning in both adults and children, although there remains considerable controversy over what it measures and how to score it. In this study we compare two scoring methods and find that correlations between them were high for 7-year-olds (.86), and dropped to a low of .47 for adults. These results demonstrate that the TOL necessarily has different construct validity in adults and children. Second, results of one method (based on errors only) show a developmental trend in performance from middle childhood to adulthood, while the other (based on errors and time) shows a developmental progression from ages 7 to 13, but not between 13-year-olds and young adults. Thus, scoring method influences the resulting developmental model.


Sujet(s)
Développement de l'enfant/physiologie , Cognition , Tests neuropsychologiques , Plan de recherche/normes , Adolescent , Adulte , Enfant , Femelle , Humains , Mâle
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE